Skip to content
Research Article Open access CC BY 4.0

Dp103 in Egyptian Patients with Breast Cancer: Prognosis to Lymph Node Metastasis

Heba G. Abd El-Aziz, Shereen S. El-Shaer, Doaa M. Abd El-Latif, M. Gomaa, Mahmoud M. Kamel

Journal of Cancer and Tumor International · pp. 1–10 · Published 18 Jul 2017

10.9734/JCTI/2017/35052

Abstract

Background: Dp103 is a multifunctional protein which binds and unwinds RNA secondary structures, therefore plays a vital role in RNA metabolism from birth to death. Aims: The present study aimed to evaluate both serum levels and tissue expressions of Dp103 and explored their possible roles in lymph node metastasis within breast cancer Egyptian patients. Methodology: Sixty patients were enrolled in this study; they were subdivided into two groups. First group included forty females newly diagnosed as primary breast cancer their age ranged from 26 to 81 and further subdivided in two groups according to lymph node involvement into twenty two patients without metastatic lymph node and eighteen patients with metastatic lymph node. Second group involved twenty females newly diagnosed as benign breast tumor their age ranged from 32 to 65, in addition to eighteen apparently healthy females aged range from 28 to 65 as controls. Serum level of both Dp103 and MMP-9 were determined using ELISA technique. CA 15.3 and CEA were determined using available commercial kits. Expression level for both Dp103 and NF-κB were estimated using qPCR. Results: Serum levels of both Dp103 and MMP-9 were significantly higher in primary breast cancer patients when compared to benign tumor and healthy females (p<0.05). As well as, the expression levels of both Dp103 and NF-κB were significantly high in metastatic lymph node when compared to benign tumor and none metastatic lymph node groups (p<0.05). Also, serum levels of both Dp 103 and MMP-9 showed the same pattern of accretion when compared to none metastatic lymph node. Significant positive correlation was found between serum Dp103 in primary breast cancer patients and CA15.3 (r=0.3195 and p= 0.044). Conclusion: Dp103 might be used as a prognostic biomarker for breast cancer progression and metastasis.  

Dp103 MMP-9 NF-κB qPCR breast cancer

References (25)

  1. 1 Matrix Metalloproteinases: Regulators of the Tumor Microenvironment [DOI]
  2. 2 Breast cancer statistics, 2019 [DOI]
  3. 3 Hallmarks of Cancer: The Next Generation [DOI]
  4. 4 Strategies for MMP inhibition in cancer: innovations for the post-trial era [DOI]
  5. 5 Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer [DOI]
  6. 6 Physiology and pathophysiology of matrix metalloproteases [DOI]
  7. 7 Study of matrix metalloproteinases and their inhibitors in breast cancer [DOI]
  8. 8 Molecular mechanisms of metastasis in breast cancer—clinical applications [DOI]
  9. 9 Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database [DOI]
  10. 10 Metastasis: new perspectives on an old problem [DOI]
  11. 11 Effect of Ablation or Inhibition of Stromal Matrix Metalloproteinase-9 on Lung Metastasis in a Breast Cancer Model Is Dependent on Genetic Background [DOI]
  12. 12 DEAD-box helicase DP103 defines metastatic potential of human breast cancers [DOI]
  13. 13 Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. [DOI]
  14. 14 An Induced Ets Repressor Complex Regulates Growth Arrest during Terminal Macrophage Differentiation [DOI]
  15. 15 Bortezomib Induces Apoptosis of Epstein-Barr Virus (EBV)-Transformed B Cells and Prolongs Survival of Mice Inoculated with EBV-Transformed B Cells [DOI]
  16. 16 Analysis of Host- and Tumor-Derived Proteinases Using a Custom Dual Species Microarray Reveals a Protective Role for Stromal Matrix Metalloproteinase-12 in Non–Small Cell Lung Cancer [DOI]
  17. 17 Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer [DOI]
  18. 18 Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer.
  19. 19 Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer [DOI]
  20. 20 Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication [DOI]
  21. 21 The Ddx20/DP103 Dead Box Protein Represses Transcriptional Activation by Egr2/Krox-20 [DOI]
  22. 22 Serum levels of matrix metalloproteinase-9 predict lymph node metastasis in breast cancer patients [DOI]
  23. 23 Evaluation of Serum Levels of HER2, MMP-9, Nitric Oxide, and Total Antioxidant Capacity in Egyptian Breast Cancer Patients: Correlation with Clinico-Pathological Parameters [DOI]
  24. 24 Evidence for U.S. Preventive Services Task Force (USPSTF) Recommendations Against Routine Mammography for Females between 40-49 Years of Age [DOI]
  25. 25 A role for hepatic metastasectomy in stage IV melanoma and breast cancer: reestablishing the surgical modality.

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

34

Page views

0

PDF downloads

5

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.